MarketCap
Facebook
X
Telegram
Ampio Pharmaceuticals Balance Sheet 2023-2008 | AMPE
Brief overview of Ampio Pharmaceuticals's assets and capital
The comparison uses five available annual reports from the 2019–2023 interval.
Assets finished at $5.7 million versus $14 million initially, losing -59%. The balance sheet contracted.
Liabilities grew more slowly than assets: -68.6% versus -59%. Expansion relied more on equity, improving funding quality.
The equity-to-assets ratio is 58.6%, compared with 46% five periods ago. The balance sheet has a substantial internal cushion.
The cash reserve occupies 71.3% of the balance sheet, previously 46.7%. It is one marker of short-term resilience.
The accumulated result is -$242.5 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall assessment
Ampio Pharmaceuticals retains a reasonably healthy balance sheet structure, which still needs support from earnings and cash flow.
Annual Balance Sheet Ampio Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -12 M | -33 M | -16.1 M | -5.06 M | -7.59 M | -8.21 M | -4.89 M | -22 M | -50.3 M | -26.3 M | -17.7 M | -11.4 M | - | - | - |
Long Term Debt |
- | 274 K | 614 K | 925 K | 1.21 M | - | - | - | 4.92 M | - | - | - | - | - | - | - |
Long Term Debt Current |
274 K | 340 K | 311 K | 284 K | 259 K | 60 K | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 3.53 M | 3.27 M | 7.41 M | 45.6 M | 4.83 M | 6.98 M | 1.13 M | 331 K | 381 K | 431 K | - | - | - |
Total Current Liabilities |
2.38 M | 1.19 M | 5.12 M | 1.83 M | 4.28 M | 1.38 M | 3.88 M | 2.13 M | 5.52 M | 3.68 M | 2.47 M | 1.64 M | 1.29 M | 4.75 M | - | - |
Total Liabilities |
2.38 M | 1.8 M | 11.5 M | 5.37 M | 7.56 M | 8.79 M | 49.5 M | 6.96 M | 12.5 M | 4.81 M | 2.8 M | 2.02 M | 1.72 M | 4.75 M | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | 85.7 K | 85.7 K | 50 K | 50 K | 50 K | - | - | - |
Retained Earnings |
-243 M | -234 M | -218 M | -201 M | -185 M | -171 M | -205 M | -153 M | -134 M | -102 M | -63.8 M | -39.8 M | -28.2 M | - | - | - |
Total Assets |
5.74 M | 13.6 M | 38.8 M | 22.9 M | 14 M | 14 M | 15.3 M | 13.6 M | 50.4 M | 70.3 M | 36 M | 25.8 M | 19.5 M | 738 K | - | - |
Cash and Cash Equivalents |
4.09 M | 12.7 M | 33.9 M | 17.3 M | 6.53 M | 7.58 M | 8.21 M | 4.89 M | 27 M | 50.3 M | 26.3 M | 17.7 M | 11.4 M | 671 K | 72 K | - |
Book Value |
3.36 M | 11.8 M | 27.3 M | 17.5 M | 6.44 M | 5.24 M | -34.2 M | 6.63 M | 37.9 M | 65.5 M | 33.2 M | 23.8 M | 17.8 M | -4.01 M | - | - |
Total Shareholders Equity |
3.36 M | 11.8 M | 27.3 M | 17.5 M | 6.44 M | 5.24 M | -34.2 M | 6.63 M | 37 M | 66.1 M | 33.1 M | 23.8 M | 17.8 M | -4.01 M | -268 K | 1.08 K |
All numbers in USD currency
Quarterly Balance Sheet Ampio Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 94 K | 185 K | 274 K | 362 K | 448 K | 533 K | 614 K | 694 K | 773 K | 851 K | 925 K | 999 K | 1.07 M | 1.14 M | 1.21 M | 1.28 M | 1.34 M | 1.41 M | 477 K | - | 477 K | 477 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.98 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.27 M | 2.59 M | 2.86 M | 1.8 M | 4.99 M | 7.12 M | 10.5 M | 11.5 M | 5.2 M | 6.35 M | 4.95 M | 5.37 M | 4.82 M | 5.52 M | 6.85 M | 7.56 M | 11.8 M | 9.78 M | 13.1 M | 8.79 M | 13.3 M | 15.4 M | 23.5 M | 49.5 M | 9.59 M | 9.33 M | 5.82 M | 6.96 M | 7.05 M | 3.22 M | 3.93 M | 12.5 M | 10.6 M | 4.61 M | 3.31 M | 4.81 M | 4.27 M | 5.07 M | 5.39 M | 2.8 M | 2.43 M | 2.79 M | 2.09 M | 2.02 M | 1.69 M | 1.5 M | 1.33 M | 1.72 M | 2.14 M | 2.38 M | 1.72 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 85.7 K | 85.7 K | 85.7 K | 85.7 K | 85.7 K | 85.7 K | 85.7 K | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K |
Retained Earnings |
-240 M | -239 M | -238 M | -234 M | -232 M | -225 M | -223 M | -218 M | -211 M | -208 M | -204 M | -201 M | -196 M | -193 M | -190 M | -185 M | -184 M | -176 M | -177 M | -171 M | -173 M | -178 M | -183 M | -205 M | -162 M | -158 M | -155 M | -153 M | -150 M | -146 M | -141 M | -134 M | -124 M | -117 M | -109 M | -102 M | -92 M | -82.7 M | -102 M | -63.8 M | -63.8 M | -63.8 M | - | - | - | - | - | - | - | - | - |
Total Assets |
7.65 M | 9.15 M | 10.7 M | 13.6 M | 18.8 M | 27.2 M | 32.8 M | 38.8 M | 22.5 M | 26.7 M | 21.7 M | 22.9 M | 15.5 M | 11.9 M | 8.85 M | 14 M | 16 M | 20.9 M | 12.6 M | 14 M | 15.6 M | 11.7 M | 14.7 M | 15.3 M | 9.39 M | 13.1 M | 10.8 M | 13.6 M | 16.8 M | 16.4 M | 21.9 M | 50.4 M | 57.1 M | 57.9 M | 62.6 M | 70.3 M | 77.2 M | 85 M | 92.6 M | 36 M | 40.8 M | 21.5 M | 25.5 M | 25.8 M | 28.4 M | 15.2 M | 16.5 M | 19.5 M | 15.2 M | 16.6 M | 19.5 M |
Cash and Cash Equivalents |
6.4 M | 6.95 M | 10.4 M | 12.7 M | 16.9 M | 22.9 M | 28.8 M | 33.9 M | 17.1 M | 20.5 M | 15.8 M | 17.3 M | 9.36 M | 4.84 M | 2.42 M | 6.53 M | 8.04 M | 12.8 M | 5.16 M | 7.58 M | 8.67 M | 4.66 M | 7.52 M | 8.21 M | 1.81 M | 4.94 M | 2.26 M | 4.89 M | 7.42 M | 6.45 M | 11.1 M | 27 M | 35.4 M | 36.8 M | 43.3 M | 50.3 M | 56.8 M | 65.6 M | 78.2 M | 26.3 M | 32.1 M | 12.5 M | 16.5 M | 17.7 M | 20.3 M | 6.8 M | 8.29 M | 11.4 M | 6.99 M | 8.37 M | 11.4 M |
Book Value |
5.38 M | 6.56 M | 7.88 M | 11.8 M | 13.8 M | 20.1 M | 22.3 M | 27.3 M | 17.3 M | 20.4 M | 16.8 M | 17.5 M | 10.7 M | 6.34 M | 1.99 M | 6.44 M | 4.14 M | 11.1 M | -468 K | 5.24 M | 2.24 M | -3.77 M | -8.86 M | -34.2 M | -199 K | 3.73 M | 5.02 M | 6.63 M | 9.77 M | 13.1 M | 17.9 M | 37.9 M | 46.5 M | 53.3 M | 59.3 M | 65.5 M | 72.9 M | 79.9 M | 87.2 M | 33.2 M | 38.4 M | 18.7 M | 23.4 M | 23.8 M | 26.7 M | 13.7 M | 15.2 M | 17.8 M | 13.1 M | 14.3 M | 17.8 M |
Total Shareholders Equity |
5.38 M | 6.56 M | 7.88 M | 11.8 M | 13.8 M | 20.1 M | 22.3 M | 27.3 M | 17.3 M | 20.4 M | 16.8 M | 17.5 M | 10.7 M | 6.34 M | 1.99 M | 6.44 M | 4.14 M | 11.1 M | -468 K | 5.24 M | 2.24 M | -3.77 M | 8.9 M | -34.2 M | 199 K | 3.7 M | 5 M | 6.63 M | 9.77 M | 13.1 M | 17.9 M | 37 M | 44.9 M | 51.3 M | 60.3 M | 66.1 M | 73.3 M | 80.2 M | 87.3 M | 33.1 M | 38 M | 18.2 M | 23 M | 23.8 M | 26.7 M | 13.7 M | 15.2 M | 17.8 M | 13.1 M | 14.3 M | 17.8 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Ampio Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
Canada
Germany
China
Israel
France
Britain
Belgium
